BUSE:NUTEX

Stock Analysis Report

Executive Summary

NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has NUTEX Investments's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.3%

NUTEX

0.08%

HU Pharmaceuticals

0.7%

HU Market


1 Year Return

-24.2%

NUTEX

7.2%

HU Pharmaceuticals

10.4%

HU Market

Return vs Industry: NUTEX underperformed the Hungarian Pharmaceuticals industry which returned 7.2% over the past year.

Return vs Market: NUTEX underperformed the Hungarian Market which returned 10.4% over the past year.


Shareholder returns

NUTEXIndustryMarket
7 Day0.3%0.08%0.7%
30 Day-4.6%0.4%-0.04%
90 Day0%4.4%-1.5%
1 Year-24.2%-24.2%13.3%7.2%13.5%10.4%
3 Year-54.3%-54.3%30.3%15.8%50.9%38.5%
5 Year-38.7%-38.7%30.7%9.2%159.6%127.1%

Price Volatility Vs. Market

How volatile is NUTEX Investments's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NUTEX Investments undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: NUTEX (HUF28.8) is trading below our estimate of fair value (HUF138.58)

Significantly Undervalued: NUTEX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate NUTEX's PE Ratio to determine if it is good value compared to the Pharmaceuticals industry average.

PE vs Market: Insufficient data to calculate NUTEX's PE Ratio to determine if it is good value compared to the Hungarian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NUTEX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: Insufficient data to calculate NUTEX's PB Ratio to determine if it is good value.


Next Steps

Future Growth

How is NUTEX Investments forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NUTEX Investments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NUTEX Investments performed over the past 5 years?

5.8%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, NUTEX Investments has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is NUTEX Investments's financial position?


In this section we usually analyse NUTEX Investments's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. NUTEX Investments has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of NUTEX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. NUTEX Investments's cash and debt levels may be found in its annual reports archived here.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when NUTEX Investments's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is NUTEX Investments's current dividend yield, its reliability and sustainability?

34.72%

Current Dividend Yield


Dividend Yield vs Market

company34.7%marketbottom25%2.2%markettop25%5.6%industryaverage3.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: NUTEX's dividend (34.72%) is higher than the bottom 25% of dividend payers in the Hungarian market (2.15%).

High Dividend: NUTEX's dividend (34.72%) is in the top 25% of dividend payers in the Hungarian market (5.62%)

Stable Dividend: Whilst dividend payments have been stable, NUTEX has been paying a dividend for less than 10 years.

Growing Dividend: NUTEX has only been paying a dividend for 7 years, and since then payments have not increased.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of NUTEX Investments's salary, the management and board of directors tenure and is there insider trading?


CEO

Gábor Csereklei 0

0yrs

Tenure

0

Gábor Csereklei serves as Chief Executive Officer for Investor Relations at NUTEX Investments Public Limited Company. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Vilmos Galamb

    Chairman & President

    • Tenure: 0yrs
  • Gábor Csereklei

    Chief Executive Officer of Investor Relations

    • Tenure: 0yrs

Board Members

  • Vilmos Galamb

    Chairman & President

    • Tenure: 0yrs

Company Information

NUTEX Investments Public Limited Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NUTEX Investments Public Limited Company
  • Ticker: NUTEX
  • Exchange: BUSE
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Ft717.574m
  • Shares outstanding: 24.92m
  • Website: https://www.nutex.hu

Location

  • NUTEX Investments Public Limited Company
  • Telepes u. 53
  • Budapest
  • 1147
  • Hungary

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NUTEXBUSE (Budapest Stock Exchange)YesOrdinary SharesHUHUFSep 1996

Biography

NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally. The company was formerly known as HUMET Trad ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 20:47
End of Day Share Price2019/10/18 00:00
Earnings2012/06/30
Annual Earnings2011/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.